nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2025, 12, v.4 20-25
张葵基于“补虚化痰祛瘀法”论治肺积经验
基金项目(Foundation):
邮箱(Email): zky0696@126.com;
DOI: 10.20065/j.cnki.btcm.20250258
摘要:

肺癌属于呼吸系统的恶性肿瘤,目前规范性及个体化的西医治疗方案具有一定的疗效,但因耐药性及毒副作用,只有部分人群获益。贵州省名中医张葵教授认为肺癌主要病机为气虚为本,尤以肺气虚为主,痰浊、瘀血、癌毒交阻于肺络,临诊辨证多为肺脾气虚、肺肾两虚、气阴两虚三个证型,提出补虚化痰祛瘀法,即补虚以补肺健脾益肾为法,兼以活血化瘀、化痰散结为法,疗效显著。现总结张葵教授治疗肺癌的临证经验,并附医案1则以佐证。

Abstract:

Lung cancer is a malignant tumor of the respiratory system. At present, the standardized and individualized Western medicine treatment schemes have certain therapeutic effects, while only part of the patients can benefit from them due to drug resistance and toxic side effects. Professor ZHANG Kui, a famous traditional Chinese medicine(TCM) doctor in Guizhou Province, believes that the main pathogenesis of lung cancer lies in qi deficiency, especially lung qi deficiency. Phlegm turbidity, blood stasis, and cancerous toxins block the lung collaterals. The patients mainly present three syndromes: lung-spleen qi deficiency, lung-kidney deficiency, and qi-yin deficiency. Accordingly, Professor ZHANG Kui proposed the methods of tonifying deficiency, resolving phlegm, and removing stasis. That is, the treatment should focus on tonifying the lung, spleen, and kidney, while also paying attention to activating blood, removing stasis and phlegm, and dissipating mass. This article introduces Professor ZHANG Kui's clinical experience in the treatment of lung cancer, with one medical case for supporting evidence.

参考文献

[1]ALLEMANI C,MATSUDA T,DI CARLO V,et al. Global surveillance of trends in cancer survival2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of18 cancers from 322 population-based registries in 71countries[J]. Lancet, 2018,391(10125):1023-1075.

[2]中华医学会肿瘤学分会.中华医学会肺癌临床诊疗指南(2024版)[J].中华医学杂志,2024,104(34):3175-3213.

[3]郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.

[4]苏婉,徐振晔.历代中医医籍中肺癌相关文献概述[J].中医文献杂志,2010,28(1):53-55.

[5]连粉红,夏小军,郭炳涛,等.原发性支气管肺癌中医病名探析[J].甘肃医药,2020,39(7):644-646.

[6]蔡绪明.名中医曹利平教授肺癌临证经验分享[C]//陕西省中医药学会.陕西省第三届名老中医药学术经验交流大会论文集.西安:陕西省中医药学会,2019:35-39.

[7]季琴,宋卿,高静东.基于现代医学视野对肺癌中医辨证分型的溯源及拓展[J].世界中医药,2024,19(12):1787-1791.

[8]沈金鳌.杂病源流犀烛[M].田思胜,整理.北京:人民卫生出版社,2006:6-73.

[9]林丽珠,王思愚,黄学武.肺癌中西医结合诊疗专家共识[J].中医肿瘤学杂志,2021,3(6):1-17.

[10]杨天兴,王笑丹,吴春华.肺癌中医证候分布规律临床研究[J].浙江中医杂志,2024,59(3):211-212.

[11]倪建成,范永飞,叶祖云.太子参化学成分、药理作用和应用的研究进展[J].中草药,2023,54(6):1963-1977.

[12]张景岳.景岳全书[M].太原:山西科学技术出版社,2006:265-266.

[13]韩珊珊,路洋,刘寨东.薏苡仁化学成分及抗肿瘤作用研究进展[J].中华中医药学刊,2024,42(9):210-219.

基本信息:

DOI:10.20065/j.cnki.btcm.20250258

中图分类号:R249;R273

引用信息:

[1]施亚楠,张葵.张葵基于“补虚化痰祛瘀法”论治肺积经验[J].基层中医药,2025,4(12):20-25.DOI:10.20065/j.cnki.btcm.20250258.

投稿时间:

2025-03-01

投稿日期(年):

2025

终审时间:

2025-04-18

终审日期(年):

2025

审稿周期(年):

1

发布时间:

2025-12-20

出版时间:

2025-12-20

检 索 高级检索

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文